YIGSR

YIGSR is a peptide that can inhibit the tumour growth and metastasis of leukaemic cells[1]. YIGSR blocks the cellular binding to laminin I via a 67-kDa laminin-binding protein, and inhibits shear-induced increase in eNOS expression of laminin cells[2].

Product Specifications

CAS Number

[110590-64-2]

Product Name Alternative

Laminin Fragment 929-933

UNSPSC

12352209

Hazard Statement

H302-H315-H319-H335

Target

NO Synthase

Type

Peptides

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/yigsr.html

Purity

99.28

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

N=C(N)NCCC[C@@H](C(O)=O)NC([C@H](CO)NC(CNC([C@H]([C@@H](C)CC)NC([C@H](CC1=CC=C(C=C1)O)N)=O)=O)=O)=O

Molecular Formula

C26H42N8O8

Molecular Weight

594.66

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]N Yoshida, et al. The laminin-derived peptide YIGSR (Tyr–Ile–Gly–Ser–Arg) inhibits human pre-B leukaemic cell growth and dissemination to organs in SCID mice. Br J Cancer. 1999 Aug; 80 (12) : 1898–1904.|[2]Gloe T, et al. The 67-kDa laminin-binding protein is involved in shear stress-dependent endothelial nitric-oxide synthase expression. J Biol Chem. 1999 Jun 4;274 (23) :15996-6002.